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Lipoprotein related receptor protein type 2 (LRP2) is highly expressed on both yolk sac and placenta. 
Mutations in the corresponding gene are associated with severe birth defects in humans, known as 
Donnai-Barrow syndrome. We here characterized the contribution of LRP2 and maternal plasma 
cholesterol availability  to maternal-fetal cholesterol transport and fetal cholesterol levels in utero in 
mice. 
Methods  
Lrp2+/- mice were mated heterozygously to yield fetuses of all 3 genotypes. Half of the dams received 
a 0.5% probucol enriched diet during gestation to decrease maternal HDL cholesterol. At E13.5 the 
dams received an injection of D7 labeled cholesterol and were provided with 1-13C acetate-
supplemented drinking water. At E16.5, fetal tissues were collected and maternal cholesterol 
transport and fetal synthesis quantified by isotope enrichments in fetal tissues by GC-MS. 
Results  
The Lrp2 genotype did not influence maternal-fetal cholesterol transport and fetal cholesterol. 
However, lowering of maternal plasma cholesterol levels by probucol significantly reduced maternal-
fetal cholesterol transport. In the fetal liver, this was associated with increased cholesterol synthesis 
rates. No indications were found for an interaction between the Lrp2 genotype and maternal 
probucol treatment. 
Conclusions  
Maternal-fetal cholesterol transport and endogenous fetal cholesterol synthesis depend on maternal 
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results suggest that the mouse fetus can compensate for decreased maternal cholesterol levels. It 
remains a relevant question how the delicate system of cholesterol transport and synthesis is 
regulated in the human fetus and placenta. 
 
Key words: lipoprotein, placenta, transport, fetus, cholesterol  
 
Introduction 
Cholesterol is important for embryonic development and fetal growth, since it is part of all cell 
membranes, a precursor for steroid hormones, and the activator of the sonic hedgehog (SHH-GLI) 
transcription pathway. Besides cholesterol synthesis by the fetus itself, it has been shown that 
maternal and fetal plasma cholesterol levels are strongly correlated during most of gestation1 and 
recent human studies have indicated that during the second trimester of pregnancy maternal 
cholesterol is transported to the fetus in significant amounts 2,3. This suggests that maternal 
cholesterol may be the most important source for the growing fetus during organ development, 
when its own cholesterol synthesis is relatively low.  
Defects in cholesterol synthesis pathways, like in Smith-Lemli-Opitz syndrome or in desmosterolosis, 
are characterized by a range of congenital birth defects, both in humans and murine models 4,5. 
Similarly, errors in the SHH-GLI transcription pathway are known to cause serious birth defects, 
ranging from mild microcephaly to severe holoprosencephaly, neural tube defects and heart defects 
6-8
. It is therefore not surprising that associations between low maternal cholesterol levels and 
adverse birth outcome have previously been described in humans 9-11. Recently, a study showed that 
also mothers with increased cholesterol levels have a higher chance of giving birth to a child with a 
congenital heart defect 12. Analyzing the effects of hypercholesterolemia in pregnant women is more 
complex since cholesterol levels are not routinely screened for during pregnancy. It is however of 










This article is protected by copyright. All rights reserved. 
organogenesis since the prevalence of diseases affecting maternal cholesterol levels such as 
diabetes and obesity are increasing rapidly among pregnant women 13. 
Maternal-fetal interfaces - the yolk sac and placenta -  are known to express a large number of 
proteins involved in cholesterol transport, which further suggests that maternal cholesterol is an 
important source of fetal cholesterol (reviewed by: 14,15). Absence of these cholesterol transporters in 
mouse models show different phenotypes, ranging from early developmental arrest and 
exencephaly in scavenger receptor class B deficient embryos 16,  to no birth defects in low density 
lipoprotein receptor knockout pups 17. 
One receptor is, however, of particular interest since it is known that mutations in this gene give a 
human phenotype with congenital anomalies, the Donnai-Barrow syndrome 18: Lipoprotein receptor 
related protein 2 (LRP2), also known as megalin, is highly expressed on both secondary yolk sac and 
placenta during pregnancy (reviewed in 19). It is known to bind a large variety of ligands, including 
LDL cholesterol and, in co-transport with cubilin, is furthermore involved in HDL cholesterol 
transport 20. Mice homozygous for Lrp2 knockout are born with severe birth defects; including 
holoprosencephaly, neural tube defects and kidney abnormalities, and die within 24 hours after 
birth 21. Although absence of functional LRP2 in the affected fetal organs itself is the most likely 
cause of the observed congenital anomalies of Lrp2-/- fetuses, a contributing effect of receptor 
function on nutrient transport in the placenta and the yolk sac is likely 22,23.  
We have very recently described that Lrp2-/- fetuses develop severe congenital heart anomalies in 
utero 24. Lrp2-/- fetuses show high penetrance of congenital heart anomalies, including common 
arterial trunk, aortic arch anomalies, straddling tricuspid valve and marked thinning of the 
ventricular myocardium. We here performed a cholesterol transport study in Lrp2-/-  mice to answer 
the question whether LRP2 on yolk sac and placenta is substantially involved in maternal-fetal 
cholesterol transport and to what extend this contributes to organ development. 
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labeled acetate in the drinking water. Based on the distribution of the labels in different tissues and 
incorporation of the acetate in newly formed cholesterol, both transport and synthesis rates could 
be calculated (Mass Isotopomer Distribution Analysis (MIDA)). As HDL and LDL particles are known 
LRP2 ligands, we hypothesized that a lack of maternal cholesterol could be contributing to the 
pathogenesis of the congenital heart anomalies in Lrp2 knockout embryos. 
To further elucidate the effect of adverse maternal cholesterol levels on maternal-fetal cholesterol 
transport and resulting cholesterol levels in the mouse fetus, we administered probucol to half of 
the dams during pregnancy. Probucol administration in mice is associated with a 60% reduction in 
total plasma cholesterol, mainly by reduction of HDL cholesterol levels 25. One of the mechanisms by 
which probucol lowers plasma cholesterol levels is by inhibition of the ATP binding cassette 
transporter A1 (ABCA1), which is crucially involved in the formation of HDL26. Analyzing the effects of 
reduced HDL levels on maternal-fetal transport may be of particular interest since maternal obesity 
and diabetes are known to lead to a reduction in HDL cholesterol, which may affect maternal-fetal 
lipid exchange characteristics 27. 
In addition, the ABC transporters Abca1 and Abcg1 are expressed in multiple compartments of the 
placenta, indicative for a synergistic function in lipid exchange during pregnancy. Although the exact 
mechanisms of action and directionalities of transplacental lipid exchange through these two 
transporters are not fully understood, a role for ABCA1 and ABCG1 in mediating efflux of cholesterol 
from human fetal endothelial cells to the fetal circulation has been suggested previously 28,29. 
 
In order to quantify the effect of Lrp2 genotype and probucol administration on maternal-fetal 
cholesterol transport and fetal cholesterol levels in utero, Lrp2 mice were bred heterozygously while 
receiving either a control or probucol supplemented diet. Stable isotope labelling was performed to 
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Lrp2 genotypes. Together, the combination of genotype and lowered maternal cholesterol 
availability by administration of probucol allowed us to determine the role of LRP2 in maternal-fetal 
cholesterol transport. 
 
Materials and methods 
Animals 
Mice with a disruption of the Lrp2 gene have been described previously 21 and were kindly provided 
by Prof. Thomas Willnow (Max Delbrück Center for Molecular Medicine, Berlin, Germany). Female 
Lrp2+/- mice were fed either RMH-B breeding and maintenance diet (AB-diets, Woerden, 
Netherlands; containing 5% fat, 23.5% protein, 42.3% carbohydrates), or the former supplemented 
with 0.5% probucol (Sigma-Aldrich, Zwijndrecht, Netherlands). The animals were housed in 
temperature controlled rooms (23  C) with a 12/12h light/dark cycle. Food and water were provided 
ad libitum throughout the experiments. After one week, the Lrp2+/- females were mated to Lrp2+/- 
males overnight, the morning after the mating was taken as E0.5. At the time of mating, females 
were between 10 and 16 weeks of age. All experimental procedures have been performed under the 
consent of the local ethical committee for animal experiments of the University of Groningen. 
 
Experimental Procedures 
Administration of stable isotopes and fetal tissues collection 
On embryonic day 13.5 (E13.5), the pregnant females received a 0.5 mg intravenous dose of 
[25,26,26,26,27,27,27]-D7-cholesterol (Cambridge Isotope Laboratories, Andover, MA) dissolved in 
20% intra-lipid (Fresenius Kabi, Den Bosch, Netherlands) by retro-orbital injection. Directly following 
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(Isotec, Miamisburg, OH) supplemented drinking water. Bloodspots were collected before 
administration of the labeled cholesterol/acetate (T=0) and twice a day, by tail bleeding on filter 
paper. At embryonic day 16.5, the females were anaesthetized with isoflurane and terminated by 
cardiac puncture. Blood was collected in EDTA containing tubes; the plasma fraction was collected 
after 15 minutes centrifugation at 2000 g at 4°C, and finally stored at -80 °C.  
Uteri of the pregnant dams were excised and kept in PBS on ice while extracting the fetuses. Fetal 
blood was collected as spots by exsanguination on filter paper. In addition, a small amount of fetal 
blood was collected using heparinized capillaries to obtain fetal plasma for the determination of 
cholesterol concentrations. Both for the stable isotope data and RT-qPCR analysis, the fetal part of 
the placenta was isolated by removal of maternal decidual tissue after excision from the uterus.  
Fetal liver, brain, the remaining carcass (from here one referred to as “fetal body”) and placenta’s 
were then collected in pre-weighed tubes, snap-frozen in liquid nitrogen and stored at -80  C for 
isotope analysis,.  
For genotyping, genomic DNA was isolated from fetal tail tip using the Extract-N-Amp™ Tissue PCR 
Kit (Sigma-Aldrich) following standard manufacturers’ protocol.  The WT allele was amplified by the 
primers Lrp2-E+T-F (5’-CATATCTTGGAAATAAAGCGACATC-3’) + Lrp2-E-R (5’-
TCTCCTGTCAGTCCCATCGTA-3’), producing a 361 bp fragment. Detection of the mutant allele was 
performed using the primers Lrp2-E+T-F + Lrp2-T-R (5’-GAGGATTGGGAAGACAATAGCA-3’), resulting 
in a 300 bp product. The PCR program utilized  as  5   C for 10 min., followed by 3  cycles of  5   C 
for  5s,      C for  5s, and      C for 45s, with a final step of 7 min. at 72 °C. 
Histological examination of the fetal hearts 
For histological examination of the fetal hearts, we isolated thoraxes of the embryos at E15.5. They 
were fixed in 4% paraformaldehyde for 48 hours and routinely processed for paraffin 
immunohistochemical evaluation, using myocardial light chain-2a (Mlc-2a) as a myocardial marker. 
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followed by rinsing with tap water for 10 min, dehydration and finally, mounted with Entellan 
(Merck, Darmstadt, Germany). To examine the effect of low maternal cholesterol on cardiac 
development in heterozygous fetuses, a total of 12 Lrp2+/- fetuses were examined both by 
histological examination as well as cardiac morphometry. We performed morphometry on the 
ventricular myocardium at E15.5 by analyzing the ratio of the compact ventricular myocardial 
volume against the total ventricular myocardial volumes. For an extensive description of the 




Pooled plasma samples from dams of the control and probucol supplemented group were subjected 
to fast protein liquid chromatography (FPLC) gel filtration using a Superose 6 column (GE Healthcare, 
Uppsala, Sweden). Samples were chromatographed at a flow rate of 0.5 ml/min and fractions of 500 
µl were collected. Individual fractions were assayed for cholesterol concentrations using a 
commercially available enzymatic assay (Roche Diagnostics, Mannheim, Germany).  
Lipid extractions and cholesterol determination 
Cholesterol was extracted from both dam and fetal bloodspots with 1 ml of 100% ethanol/acetone 
(1:1 v/v) for gas chromatography/mass spectrometric analysis according to 31. Prior to the lipid 
extractions, 10% PBS-tissue homogenates were obtained from whole tissue using a Tissuelyser LT 
(Qiagen, Hilden, Germany), followed by total lipid extraction according to Bligh and Dyer 32. A 
subfraction of the total lipid tissue extracts was emulsified using 2% triton X-100, after which 
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Gas chromatography/mass spectrometry (GC/MS) 
For GC/MS, unesterified cholesterol from both bloodspots and tissue extracts was derivatized using 
N,O-bis-(trimethyl)trifluoroacetamide (BSTFA) / 1% trimethylchlorosilane (TMCS) at room 
temperature and analysed by quadrupole mass spectrometry. Ions monitored were m/z 458-465 
corresponding to the m0-m8 mass isotopomers. The fractional isotopomer distribution measured 
was corrected for the fractional distribution due to natural abundance of 13C and 2H by multiple 
linear regression as described by Lee et al. 33 to obtain the excess fractional distribution of mass 
isotopomers resulting from isotope dilution and isotope incorporation of the administered labels. In 
this approach, fractional enrichment of the IV administered D7 cholesterol (M7) in the fetal tissues 
represents the relative transport of maternal cholesterol to the fetal tissues and was calculated by 
dividing the fractional enrichment of M7 within each of the respective fetal tissues by the fractional 
enrichment of M7 in the plasma of the mother at the time of termination (72 hours).   
MIDA calculations 
The MIDA (Mass Isotopomer Distribution Analysis) approach was used to estimate de novo 
cholesterol synthesis in both fetus and dam 34-36. The MIDA algorithm allows us to estimate the 
fractional contribution of newly synthesized cholesterol from a non-accessible precursor pool. The 
first step of this algorithm is the calculation of the ratio of mass-isotopomer distributions of M1 and 
M3 due to incorporation of the precursor 1-13C-acetate. By comparing these ratios to theoretical 
multinomial curves, in which precursor pool enrichment is plotted against the ratios of M1 and M3, 
the corresponding precursor pool can be estimated. Next, from a curve in which M1 and M3 are 
plotted against precursor pool enrichment, mass-isotopomer distributions of the newly synthesized 
cholesterol can be estimated. The ratio of the measured fractional distribution of cholesterol and 
the estimated fractional distribution in the newly synthesized cholesterol gives the fractional 
contribution of newly synthesized cholesterol in the pool, and is defined as the fraction of the 
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RNA isolation and RT-qPCR 
In total, placenta and liver from 10 Lrp2+/- fetuses per group (that were not used for the lipid 
extractions), originating from five independent litters, were stored at -80   C. RNA was extracted with 
TriReagent (Sigma, St. Louis, MO) to obtain total RNA fractions and quantified using a 
Nanodrop2000c (ThermoScientific, Pittsburgh, PA, USA). Real-time quantitative PCR were performed 
on a 7900HT fast real-time PCR system (Applied Biosystems, Foster City, CA) as previously described 
37. The qPCR data were normalized against the geometric mean of 36b4 (Rplp0) and B-actin, (Atcb) 
performed as separate runs.  Primer sequences were used as previously described 34-36. 
Statistics 
Results of the stable isotope data and cholesterol measurements were analysed by a univariate 
model (Pearson), according to genotype, experimental group and litter of origin 38, using SPSS v20 
(SPSS Inc., Chicago) or Mann–Whitney U test. Significance was assumed when p<0.05 according to 
Tukey post hoc test or Mann–Whitney U. Significance levels are denoted as follows: * p<0.05, ** 
p<0.01 and ***p<0.001. 
 
Results 
LRP2 does not play a quantitative role in maternal-fetal cholesterol transport during the second 
half of murine pregnancy 
Lrp2 mice were bred heterozygously, allowing us to investigate the influence of all three possible 
genotypes on maternal-fetal cholesterol transport and resulting fetal cholesterol levels in utero. 
Stable isotope labeling and Mass Isotopomer Distribution Analysis (MIDA) were applied to 
characterize maternal-fetal cholesterol transport and determine contributions of endogenously 
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independent litters, were analyzed within the control group. To directly compare genotypes within 
one litter, each litter contained at least one wild type and one knockout fetus. For the wild type and 
heterozygotes the average total fetal body weights were similar, while the Lrp2-/- fetuses showed 
severe growth retardation (p<0.001; Figure 1A). Despite the apparent difference in fetal weight, 
placental weights between the three genotypes were identical (Figure 1B).  
Seen the previously shown expression of Lrp2 in the maternal-fetal interfaces of the yolk sac and 
placenta, we analyzed whether absence of functional LRP2 protein would affect total fetal 
cholesterol concentrations in utero. Total fetal cholesterol concentrations were on average 1.7 mg/g, 
no differences were observed between the three genotypes. Cholesterol concentrations in the fetal 
brain, another known site of Lrp2 expression, were overall higher than for other fetal tissues, 
averaging 2.7 mg/g, though the levels of cholesterol were not affected by genotype (Figure 1C).  
Furthermore, the genotype had no influence on neither the measured fractional enrichments of D7 
cholesterol (Supplementary figure 1), nor the calculated maternal contributions of cholesterol for 
the fetal body and brain (Figure 1D). The observed fractional synthesis rates were also unchanged in 
the fetal body. An exception is the fetal brain, were fractional synthesis rates within the knockouts 
were on average 20% increased relative to wild type and  heterozygous fetuses (Figure 1E, P=0.02 
and P=0.014, respectively).  
 
Probucol administration during pregnancy decreases maternal plasma cholesterol and maternal-
fetal cholesterol transport  
Probucol was administered to half of the dams as a model for decreased cholesterol availability to 
the fetus during pregnancy. Parameters for the dams from the control and probucol treated group 
(n=5 per group) are listed in Table 1, no differences in body weight, liver weight, liver cholesterol 










This article is protected by copyright. All rights reserved. 
and at E16.5 of pregnancy, total plasma cholesterol in the dams were strongly decreased relative to 
the control group (Figure 2A, P<0.001, Mann–Whitney U). Pooled plasma samples of the dams at 
E16.5 were subjected to FPLC profiling, indicating that probucol treatment leads to a significant 
decrease of mainly HDL cholesterol, while a smaller reduction in LDL cholesterol was observed 
(Figure 2B).  
Despite significantly decreased maternal plasma cholesterol levels, both decay curves of the D7 label 
after intravenous administration as well as fractional contributions of the D7 cholesterol label 
indicated no differences between dams from the control and probucol treated dams (Figure 3A, 
p=0.187, repeated measurement ANOVA). The fractional contributions of newly synthesized 
cholesterol determined by MIDA and the estimated precursor pool enrichments were further not 
different between dams from the control and probucol treated group after provision of 2% 1-13C 
acetate drinking water (Figure 3B+C, p=0.792 and p=0.318 respectively). The estimated precursor 
pools in the dam blood were lower in both the control and probucol supplemented group at the 8 
hour time point compared to later time points, suggesting that from the 8 hour time point on steady 
state was achieved (P-treatment =0.318). 
To determine if decreased maternal plasma cholesterol levels would affect maternal-fetal 
cholesterol transport and fetal cholesterol levels, we measured the fractional enrichments of the D7 
label for relevant fetal tissues from the control and probucol supplemented group. Fetal weights for 
the two groups isolated are shown in Figure 4A, no differences were observed for total fetus weights 
nor any of the fetal organs analyzed, i.e., brain and liver. Linear regression analysis showed that the 
average fractional D7 enrichments per dam were strongly correlated with maternal plasma 
cholesterol levels at the time of isolation (E16.5, Figure 4B, p<0.001). Significant contributions of 
maternally derived cholesterol were evident for all fetal tissues within the control group, averaging 
from 50.7% in the fetal blood to 35.0% for the fetal body. Only limited contributions of maternal 
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the probucol treated group were further 50% decreased relative to control in all fetal tissues (Figure 
4C, p<0.001). Fetal plasma cholesterol levels were determined for 5 plasma pools within the control 
and probucol group and were found to be on average 20% decreased in the probucol group (2.24 
mmol/l and 1.80 mmol/l respectively, p=0.032; Figure 4E). Despite this apparent reduction in 
maternal and fetal plasma cholesterol concentrations upon probucol treatment, fetal tissue 
cholesterol levels were largely unchanged, with the exception of the fetal liver, were a slight but 
significant increase in cholesterol levels was observed (Figure 4D, p=0.001).  
 
Decreased maternal-fetal cholesterol transport by probucol treatment is associated with increased 
synthesis rates in the fetal liver and blood 
With maternally derived contributions of fetal cholesterol decreased and largely unchanged 
cholesterol levels in the fetal tissues upon probucol treatment, we turned our attention to the MIDA 
to determine if synthesis rates would be increased in the fetal tissues. Fractional synthesis rates as 
measured in the maternal blood at the time of isolation were similar between the control and 
probucol treated dams, averaging to 12.9%. Fractional synthesis rates as measured in the fetal 
tissues were much higher than in the dam, ranging from 20.9% in the fetal blood to 13.4% in the 
fetal brain. Synthesis rates were further slightly increased in the fetal blood (27.0%) and liver (29.0%) 
for fetuses from the probucol treated group relative to control, while synthesis rates were 
unchanged for the fetal brain (Figure 5A, p=0.015, p=0.021 and p=0.959 respectively). Fractional 
synthesis rates in the remaining fetal body were not statistically different (p=0.130). 
Furthermore, absolute contributions of newly synthesized cholesterol in the fetal liver of both 
groups, calculated by multiplying tissue levels of cholesterol per gram of tissue with the FSR, showed 
an highly significant inverse correlation with absolute contributions of maternally derived 
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definitionem not valid for a growing tissue, we examined the possibility that this correlation may 
relate to differences in fetal liver weight, which was not the case (Figure 5B, r2= 0.023, p=0.578). 
Moreover, for the fetal brain, which relies mostly on endogenous synthesis during this stage of 
pregnancy, this correlation was absent (r2 = 0.091). 
Since these results could be explained both by an increase in fetal hepatic synthesis rates as well as 
decreased efflux, we analyzed gene expression levels of the most relevant genes involved. Overall, 
the transcriptional levels of the cholesterol transporters Abca1 and Abcg1 in the fetal liver were not 
different between control and the probucol treated group. Next, we measured transcription levels of 
several genes involved in cholesterol synthesis, none of which reached statistical significance (Figure 
5C, Hmgcr (p=0.206), Sqle, (p=0.391) and Mvk, (p=0.268).  
Alternatively, changes in the observed FSR may relate to underlying differences in the acetyl-CoA 
pool, translating to changes in the observed precursor pool enrichments. However, estimated 
precursor pool enrichments in the fetal blood and liver were not significantly different from those in 
the dams’ blood at the time of termination, averaging to 9.2%. Precursor pool enrichments in the 
fetal body and brain were lower compared to those of the fetal liver and blood (7.3% and 5.7% 
respectively) but no differences between the control and probucol group were observed for any of 
the fetal tissues (Figure 5D). Finally, theoretical distributions of maternally derived cholesterol, 
newly synthesized and unaccounted cholesterol were calculated for the fetal body and fetal livers 
from the control and probucol supplemented group. These results indicate that a larger percentage 
of the cholesterol pool in these tissues may be comprised of cholesterol that is not derived from the 
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Decreased efflux capacity of the placenta by probucol may contribute to the observed reduced 
plasma cholesterol levels in the fetus 
The placenta constitutes a direct interface between the maternal and fetal circulation that 
contributes to the transport of cholesterol to the fetus. Since probucol significantly reduced 
maternal-fetal cholesterol transport, we analyzed the placentas of the corresponding fetuses (n=8 
per group). Placental weights are shown in Figure 6A, showing no differences between placentas of 
the control and probucol group (p=0.527). Cholesterol concentrations in the placenta showed a 
trend towards lower levels in the probucol group compared to control (Figure 6B, p=0.105). 
Fractional enrichments of the D7 label were similar to those observed in the maternal blood, 
translating to a large fractional contribution of maternally derived cholesterol, averaging to about 
80% for both groups. Both fractional enrichments of the D7-cholesterol label and calculated 
maternal contributions were not changed for placentas of the probucol group (Figures 6C and D). 
Fractional synthesis rates as determined by MIDA were similar to those observed in the maternal 
blood at E16.5, averaging to about 11%, with no apparent differences between the control and 
probucol group.  
Since only a trend towards reduced cholesterol levels was observed in the probucol supplemented 
group and contributions of maternally derived cholesterol were found to be similar between the two 
groups, we analyzed transcript levels of several key lipoprotein receptors mediating cholesterol 
uptake in the placental trophoblast. Expression of the low density lipoprotein receptor (Ldlr) was 
significantly increased for placentas from the probucol treated group, while transcript levels of 
scavenger receptor class B type I (Srb1) were unchanged (Figure 6F, p=0.019 and p=0.743 
respectively).  
Additionally, we analyzed transcript levels for several transporters from the ATP-binding cassette 
family and phospholipid transfer protein (Pltp), all of which have been implemented in mediating 
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decreased in the probucol supplemented group and unchanged for Abcg1, transcript levels for Pltp 
were significantly decreased upon probucol treatment (p=0.005).  
 
Heart anomalies associated with LRP2 knockout do not relate to local cholesterol uptake or 
maternal cholesterol levels 
Lrp2 is expressed in several tissues contributing to the development of the fetal heart. Consequently, 
Lrp2-/- fetuses show a range of severe cardiac abnormalities that may relate to cholesterol 
availability in utero, especially common arterial trunk and ventricular myocardial thinning 24. Local 
uptake of cholesterol, presented as the fractional enrichments of the IV administered D7 label, is 
shown in Figure 7A. Even when standardized to enrichments in the wild type fetal hearts within the 
same litter, fractional enrichments showed no differences between the three genotypes (ANOVA, 
p=0.642).  
 
Finally, we tested the possibility that strongly reduced maternal plasma cholesterol levels during 
pregnancy may induce heart defects in the otherwise normally developing Lrp2 +/- fetuses. Histology 
of the fetal heart for both the control and probucol supplemented groups revealed no indication for 
disturbed cardiac development, showing normal septation of the outflow tract and development of 
the ventricular septa (Figure 7B). Furthermore, no differences were observed in the thickness of the 
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Discussion 
Low density lipoprotein-related receptors (LRPs) comprise a group of multifunctional endocytic cell 
surface receptors, likely to have acquired complex evolutionary intertwined functions between lipid 
metabolism and developmentally regulated signaling pathways 39.   
LRP2 is the largest receptor of this family. It is implemented in the internalization of a large variety of 
ligands of potential importance during pregnancy, including cholesterol containing lipoprotein 
particles 20,40. Although Lrp2 is expressed on maternal-fetal interfaces of both the yolk sac and the 
placenta during human and murine pregnancy, a quantitative role in maternal-fetal cholesterol 
transport has not been investigated 41. Using a heterozygous breeding approach in combination with 
stable isotope labeling, we aimed to quantify the effect of absence of LRP2 during pregnancy on 
maternal-fetal cholesterol transport and the resulting cholesterol levels in the mouse fetus.  
Overall, no differences were found in the relative abundance of labeled cholesterol or calculated 
maternal contributions between Lrp2 genotypes in our mouse model. Furthermore, despite a 
significant effect of LRP2 knockout on fetal body weight, genotype had no discernible influence on 
fetal cholesterol levels or calculated synthesis rates in utero. An exception was the fetal Lrp2-/- brain, 
which showed higher fractional synthesis rates compared to those of wild type and heterozygous. 
The low fractional D7 enrichments found in the fetal brain concur with a strong dependence on 
endogenous cholesterol synthesis for the fetal brain at this stage and were further not affected by 
genotype. This suggests that the contributing effect of maternal-fetal transport is likely negligible for 
brain cholesterol levels and that  loss of Lrp2 expression in the developing nervous system itself 
gives rise to the observed neural tube defects, severely affecting further brain development 22,42,43. 
This suggests that the observed increase in cholesterol synthesis rates are likely the result of 
structural differences in the Lrp2-/- brain that may relate to underlying differences in cell populations, 
having different synthesis and/or turnover rates, or (dys)functioning of the blood-brain-barrier itself. 
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does not critically depend on the presence of functional LRP2 during this time of pregnancy. This 
suggests that either transport of alternate ligands or defects in local signaling pathways during 
development are a more likely cause of the observed heart and brain defects 22,40,42. 
In addition to studying the effect of genotype on maternal-fetal cholesterol transport, we used 
probucol as a model for decreased cholesterol availability to the fetus. Analysis of the maternal 
blood confirmed that probucol treatment was effective in reducing plasma cholesterol levels in the 
dam with more than 60% during pregnancy, mainly by reduction of HDL cholesterol. Since a 
significant part of the fetal cholesterol is derived from the mother during pregnancy, we anticipated 
a reduction in maternal-fetal cholesterol transport as well as a potential interaction with the Lrp2 
genotype. 
In line with previous research in mice, significant fractional contributions of labeled cholesterol were 
found in fetal tissues, indicating that a large part of the fetal cholesterol pool is indeed maternally 
derived 4. Maternal contributions were further significantly lowered for the probucol treated group, 
suggesting that probucol was successful in reducing maternal-fetal cholesterol transport. Since the 
fetal mouse brain is considered to rely mostly on endogenous cholesterol synthesis at this stage of 
pregnancy, only limited maternal cholesterol contributions were found, corresponding to values 
found previously 4. 
Interestingly, despite the observed reduction of maternal-fetal cholesterol transport for the 
probucol treated fetuses, overall cholesterol levels and synthesis rates as measured in the placenta 
were not significantly changed compared to placentas of the control group. In the current view of 
placental cholesterol metabolism, the placenta largely relies on the uptake of maternally derived 
cholesterol. Although we have not explicitly addressed endogenous placental cholesterol synthesis, 
our data do not give indications that it plays a significant role in our murine model system. This view 
is supported by the multitude of different lipoprotein receptors found to be expressed on the apical 
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Although it is uncertain to what extend esterified cholesterol from the placental pool exchanges with 
maternally derived cholesterol, one interpretation of these results would be that the placenta, at the 
administered dose of probucol, can still compensate for the decrease in maternal cholesterol 
availability by increasing transport into the trophoblast through upregulation of lipoprotein 
receptors, in order to maintain cholesterol homeostasis. This view is supported by the association 
with the increased expression of the placental Low Density Lipoprotein receptor (LDLR) in our model, 
which is considered, together with SR-BI, as a key lipoprotein receptor within the placental 
trophoblast 45-48. This may suggest that in mice extra-embryonic tissues may take up more LDL 
cholesterol from the maternal blood when maternal HDL concentrations are low. 
Efflux of placental cholesterol to the fetal circulation is thought to be mediated by endothelial cells 
on the fetal side of the placenta, potentially mediated by the ABC transporters, ABCG1 and ABCA1 29. 
Probucol supposedly acts by selective inhibition and inactivation of ABCA1 in the plasma membrane 
but has limited effects on ABCA1 transcript levels itself 49,50. Although the exact absolute 
contributions of the yolk sac and placenta in cholesterol transport to the fetus remain to be 
accurately determined throughout murine pregnancy, probucol mediated inhibition of efflux to fetal 
HDL through ABCA1 is likely contributing to the observed reduction in maternal-fetal cholesterol 
transport and lowered fetal plasma cholesterol levels 48. 
In addition to a role for ABC transporters, endothelial cells facing the fetal circulation are a major site 
of phospholipid transfer protein (PLTP) expression, likely to secrete active PLTP to promote 
cholesterol efflux from cells to HDL-apolipoproteins and HDL acceptors 51,52. The reduced expression 
levels of placental Pltp found might further add to the idea that probucol, either directly or 
indirectly, interferes with the efflux capacity of the placenta, corresponding to previously performed 












This article is protected by copyright. All rights reserved. 
Interestingly, despite a strong decrease in the contributions of maternal cholesterol, probucol, 
treatment lead to a significant increase in hepatic cholesterol levels in the mouse fetus, whereas 
cholesterol levels in the remaining fetal body and brain were unchanged. Furthermore, endogenous 
cholesterol synthesis, measured using MIDA, indicated that contributions of newly synthesized 
cholesterol in the fetal liver and fetal blood were modestly increased upon treatment with probucol. 
Since it is currently unknown whether probucol can cross the placenta and its presence cannot be 
deduced by measuring transcript levels of Abca1 itself, we speculate that either inhibition of ABCA1 
in the fetal liver and/or placenta may explain the observed reduction of maternally derived 
cholesterol and increased contributions of newly synthesized cholesterol in our model.  
High fetal growth rates during the end of gestation likely induce a higher demand for fetal 
cholesterol, where endogenous synthesis provides a large part of the fetal cholesterol, as is reflected 
by high expression and activity of genes involved in cholesterol synthesis 53,54.  At the same time, this 
represents one of the caveats of the MIDA approach, since this method assumes that cholesterol 
exchange is in a steady state situation, which can never be the case in a rapidly growing fetus. 
Despite these limitations, absolute contributions of newly synthesized cholesterol in the fetal liver 
showed a highly significant, inverse correlation with the contribution of maternally derived 
cholesterol. This association could not be explained by differences in individual liver weights, 
representing the total cholesterol pool, nor could be related to underlying differences in observed 
precursor pool enrichments. Together these results suggest that the mouse fetus can most likely 
counteract for a decrease in maternally derived cholesterol by a compensatory increase in 
cholesterol synthesis rates in fetal tissues, especially the fetal liver, as has been suggested before 
55,56. 
Strikingly, these results are reminiscent of previous studies using LXR agonists during murine 
pregnancy, that lead to increased maternal-fetal cholesterol transport. Furthermore, these studies 
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most likely caused by upregulation of Abca1 within the fetal-placental axis 37,48.  Our data and 
previous studies provide reasonable indications that excretory pathways to fetal HDL are already 
functional in the fetal mouse liver and would implement an important role for placental and fetal 
ABCA1 in this process 37,57. Although interpretation of our data is hampered by a non-steady state 
condition and missing information about absolute fetal growth rates during the time of 
measurement, a possibility is that the reduced maternal contributions upon probucol treatment 
reflect a decrease in maternal-fetal exchange of cholesterol instead of reflecting net import, as this 
could possibly account for the missing cholesterol in our model.  Considering that ABCA1 is 
expressed in multiple compartments of the murine placenta, this is an interesting possibility for 
further studies. 
Finally, in addition to a role for LRP2 in mediating maternal-fetal cholesterol transport, results from 
previous studies have shown that Lrp2 is expressed in several tissues contributing to the 
development of the fetal heart 21,58.  We have recently extended these observations by 
demonstrating that Lrp2 is expressed in all cell populations involved in the formation and septation 
of the outflow tract and compaction of the ventricular myocardium 24. Consequently, Lrp2-/- fetuses 
show a near complete penetrance of severe cardiac defects, that we hypothesized to originate from 
a reduced ability for cholesterol uptake within any of the cell populations involved 24. However, since 
fractional enrichments of the labeled cholesterol in the fetal heart were shown to be independent of 
the Lrp2 genotype, our data cannot exclude the possibility that ligands other than cholesterol are 
related to the observed cardiac anomalies.  
Additionally, we examined the possibility that heterozygosity for Lrp2, in combination with strongly 
reduced maternal cholesterol levels by probucol treatment, would interact to induce heart defects in 
the heterozygous offspring. Despite a significant reduction of maternally derived cholesterol by 
probucol in fetal tissues, we observed none of the cardiac anomalies present in the Lrp2-/- offspring. 
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fetuses, are not related to the concentration of cholesterol but more likely the result of disturbed 
signaling or uptake of other potentially important ligands, which has been suggested previously 22,42 
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LRP2 – Low Density Lipoprotein Related Receptor 2 
SHH – Sonic HedgeHog 
Probucol - 4,4'-[propane-2,2-diylbis(thio)]bis(2,6-di-tert-butylphenol) 
HDL – High Density Lipoprotein 
LDL – Low Density Lipoprotein 
IDL – Intermediate Density Lipoprotein 
VLDL – Very Low Density Lipoprotein 
ABCA1 – ATP Binding Cassette type A1 
ABCG1 – ATP Binding Cassette type G1 
LDLR – Low Density Lipoprotein Receptor 
HMGCR - 3-hydroxy-3-methylglutaryl-CoA reductase 
SQLE - Squalene Epoxidase 
MVK - Mevalonate Kinase 
PLTP - Phospholipid Transfer Protein 
SR-BI - Scavenger Receptor Class B member 1 
LXR - Liver X Receptor 
E13.5 – Embryonic Day 13.5 
EDTA - Ethylenediaminetetraacetic acid 
PBS - Phosphate Buffered Saline 
FPLC - Fast Protein Liquid Chromatography 
RT-qPCR – Reverse Transcription Quantitative Polymerase Chain Reaction 
D7 cholesterol - Cholesterol-25,26,26,26,27,27,27-d 
1-13C acetate - Sodium acetate-1-13C 
MIDA – Mass Isotopomer Distribution Analysis 










This article is protected by copyright. All rights reserved. 
BSTFA - N,O-bis-(trimethyl)trifluoroacetamide 
TMCS – Trimethylchlorosilane 
FSR – Fractional Synthesis Rate 
SD – Standard Deviation 
 
 
Table 1. Dam parameters at hysterectomy  
    







Body weights (g) 31.7 +/- 2.6 35.3 +/- 3.9 
Liver weight (g) 1.53 +/- 0.24 1.64 +/- 0.24 
Liver weight/BW (%) 4.84 +/-  0.69 4.64 +/- 0.47 
Cholesterol liver (mg/g) 2.67 +/-  0.13 2.58 +/- 0.18 
   Litter size (n) 
 
7.8  +/- 3.3 
 
8.6 +/- 1.3 
 
 
Table 1. Parameters for the pregnant dams from the control and probucol treated group at embryonic day 16 
(E16.5), used for the stable isotope experiments. None of the parameters were statistically significant between 
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Figure legends:  
Figure 1. Overview of the stable isotope labeling results to characterize maternal fetal cholesterol transport 
and fetal cholesterol levels depending on Lrp2 genotype. Data for fetuses from the control group is shown, 
according to genotype. The influence of genotype on the resulting fetal (A) and placental weights (B) are 
shown. (C) Cholesterol concentrations as measured in the fetal tissues, white bars represent the results for the 
Lrp2
+/+
 fetuses, grey bars Lrp2
+/-
  and black bars Lrp2
-/-
. (D) Contributions of maternally derived cholesterol as 
calculated from fractional D7 enrichments in the dam blood and fetal tissues. (E) Fractional contributions of 
newly synthesized cholesterol as determined by Mass Isotopomer Distribution Analysis (MIDA). In total, 24 
fetuses were analyzed according to genotype (n=8 each). Each litter contained at least one wild type and one 
knockout fetus. Data represent mean +/- SD. 
 
Figure 2. (A) Total plasma cholesterol levels for the dams after 1 week on the control and probucol 
supplemented diet (prior to mating) and during pregnancy, white bars represent dams from the control group, 
black bars the probucol supplemented group. (B) Fast Protein Liquid Chromatography (FPLC) profiles of pooled 
plasma samples of the pregnant dams from the control (solid line) and probucol supplemented (dotted line) 
group at day 16 of pregnancy. Data represent mean +/- SD. 
 
Figure 3. (A) Fractional enrichment of D7-labeled cholesterol in the maternal blood over 72 hours after 
intravenous administration. Data points represent actual measurements +/- SD, lines represent the averages of 
individual dam curve fittings in SAAMII, of dams from the control (continuous line) and probucol treated 
groups (dotted line) (B). Fractional contributions of newly synthesized cholesterol in the dam blood after 
provision of 2% 1-
13
C acetate drinking water. (C) Estimated fractional precursor pool enrichments for dams 
from the control and probucol supplemented diet, measured at six different time points after provision of 2% 
1-
13
C acetate in the drinking water. At the 8 hour time point, fractional precursor enrichments were 
significantly lower compared to later time points for both groups, (2-way repeated measurement ANOVA) 
while overall no differences were observed between the two groups (p= 0.318), suggesting a steady state 
condition over the time measured. Data represent mean +/- SD, n=5 dams per group.  
 
Figure 4. Characterization of maternal-fetal cholesterol transport using stable isotope labeling and cholesterol 
levels for fetuses within the control and probucol supplemented group. (A) Weights for the analysed fetal 
organs isolated at E16.5, error bars represent the SD of the individual total fetus weights. (B) Regression plot 
showing the average fractional D7 enrichments for the fetuses plotted against the plasma cholesterol 
concentration in the dams of the control and probucol supplemented group (n=10). (C) Calculated fractional 
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white bars represent fetuses from the control group, black bars fetuses from the probucol group. (E) Plasma 
cholesterol levels for fetuses from the control (open bar) and probucol treated (filled bar) group (n=5 pools per 
group). All data represent mean +/- SD 
 
Figure 5. Contributions of newly synthesized cholesterol within the fetus shown for both the control and 
probucol treated groups, calculated by Mass Isotopomer Distribution Analysis (MIDA). (A) Fractional synthesis 
rates as calculated for the dam blood at E16.5 and fetal organs, defined as the fraction of the cholesterol pool 
synthesized per unit of time. White bars represent fetuses from the control group, black bars the probucol 
supplemented group. (B) Scatter plot and linear regression of the absolute contributions of newly synthesized 
cholesterol against the absolute contributions of maternally derived cholesterol for the individual fetal livers 
from the control and probucol treated groups (Calculated by multiplying the fractional contributions of newly 
synthesized and maternally derived cholesterol with the cholesterol concentrations in the individual fetal liver 
samples, n=16). (C) Relative gene expression levels for the fetal liver. (D) Estimated precursor pool 
enrichments as observed in the dam blood at E16.5 and fetal organs. All data are shown as mean +/- SD. 
 
Figure 6. Analysis results for the placentas of the fetuses from the control (white bars) and probucol (black 
bars) treated group at E16.5 (Lrp2
+/-
, n=8 per group). (A) Average placental weight, (B) cholesterol levels, (C) 
fractional D7 enrichments, (D) calculated fractional contributions of maternally derived cholesterol and (E) 
fractional contributions of newly synthesized cholesterol. (F) Gene expressions for Lrp2
+/-
 placentas from the 
control and probucol treated group (n=10 per group). 
 
Figure 7. Cholesterol uptake within the fetal heart per genotype and cardiac phenotype of the Lrp2
+/-
 mice 
with and without probucol treatment. (A) Fractional enrichments of the D7 administered label, standardized to 
fractional enrichments for the hearts of wild type fetuses within the same litter. (B) Myocardial Light Chain-2a 
(Mlc2a) staining as myocardial marker of global cardiac development. No differences were observed in the 
outflow tract region (OFT), there is normal septation of the aorta (Ao) and pulmonary trunk (Pt). Both groups 
display an intact ventricular septum around the mitral valve (MV) and tricuspid valve (TV), without anomalies 
of the atrioventricular valves. (C) Ratios of compact myocardium versus total myocardium for fetuses from the 
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